The Federal Trade Commission on Tuesday said it is challenging hundreds of alleged "junk" patents held by pharmaceutical companies for 20 brand-name drugs, including Novo Nordisk's blockbuster diabetes drugs Ozempic, Saxenda and Victoza.The announcement expands the Biden administration's effort to crack down on alleged patent abuses by the pharmaceutical industry. The FTC has argued that drugmakers are needlessly listing dozens of extra patents for branded medications to keep their drug prices high and stal ...

Danish pharma goliath, Novo Nordisk (NVO) , is slated to report first-quarter 2024 results on May 2, before the opening bell.The Zacks Consensus Estimate for the company’s first-quarter revenues is pegged at $9.23 billion, while the same for earnings is pinned at 77 cents per share, both indicating significant increases from the year-ago quarter.Revenue growth in the first quarter of 2024 is expected to have been driven by strong demand for Novo Nordisk’s diabetes and obesity care medicines, especially sema ...

aprott Novo Nordisk A/S (NVO) secured the FDA approval for Wegovy, the weight loss version of the compound called semaglutide, for the indication of reducing risks of major cardiovascular adverse events ('MACE') in early March. Novo Nordisk is already enjoying significant commercial success with the type 2 diabetes version of semaglutide called Ozempic, and more recently, Wegovy is off to a strong start and would have higher uptake if it were not for the supply constraints as demand is exceeding supply. The ...

In the latest trading session, Novo Nordisk (NVO) closed at $126.16, marking a -1.93% move from the previous day. This change lagged the S&P 500's daily gain of 0.02%. On the other hand, the Dow registered a loss of 0.11%, and the technology-centric Nasdaq increased by 0.1%.The drugmaker's stock has dropped by 0.6% in the past month, exceeding the Medical sector's loss of 4.52% and the S&P 500's loss of 3.01%.Investors will be eagerly watching for the performance of Novo Nordisk in its upcoming earnings dis ...

The U.S. Senate has launched an investigation into the high price of Novo Nordisk's popular weight loss and diabetes drugs Ozempic and Wegovy in the United States, versus other countries where the drugs are sold.The investigation into the Danish drugmaker was announced by Sen. Bernie Sanders, the Vermont Independent who chairs the Health, Education, Labor and Pensions (HELP) Committee."The scientists at Novo Nordisk deserve great credit for developing these drugs that have the potential to be a game changer ...

Good news could be just around the corner for two drugmakers not named Novo Nordisk.Ozempic and Wegovy are the rock stars of the biopharmaceutical world. When celebrities talk about a prescription drug, it has reached the big time. And that's what has happened with Novo Nordisk's two blockbusters. The success of Ozempic and Wegovy has also helped Novo Nordisk become a rock star for investors. Shares of the big drugmaker have skyrocketed nearly 240% over the last three years.Don't worry if you think you've m ...

Here at Zacks, we offer our members many different opportunities to take full advantage of the stock market, as well as how to invest in ways that lead to long-term success.One of our most popular services, Zacks Premium offers daily updates of the Zacks Rank and Zacks Industry Rank; full access to the Zacks #1 Rank List; Equity Research reports; and Premium stock screens like the Earnings ESP filter. All are useful tools to find what stocks to buy, what to sell, and what are today's hottest industries.It a ...

It's not only spending its capital on developing new drugs.Hardly for the first time in recent weeks and months, Novo Nordisk (NVO 2.08%) had a good trading session on the stock market Monday. The company's shares enjoyed a more than 2% boost on the day, comparing favorably to the 0.9% rise of the S&P 500 index. Investors were cheered by the fact that the Denmark-based pharmaceutical upstart is maintaining its stock repurchase program.Stock buyback program updateNovo Nordisk said in a brief update that it h ...

These stocks probably won't be getting much cheaper.As investing legends like Warren Buffett probably know better than anyone, there's something satisfying about buying shares of a company you intend to hold for the rest of your career as an investor. By making a commitment to remaining patient for the long haul as the money trickles in, you're also demonstrating to yourself that you're serious about using the savvy investing strategies that it takes to improve your financial life in a durable fashion.Psych ...

Biotech stocks offer the possibility of groundbreaking medical advancements alongside the potential for explosive growth. While the sector carries inherent risks, a select group of biotech companies possesses the potential to deliver substantial returns in the coming years. It is no surprise that investors continue to turn to this sector as advancements in technology strengthen its growth prospects. From revolutionary gene therapies to cancer research, the possibilities are endless. Furthermore, the converg ...